Department of Haematology Test Name Result Unit Bio. Ref. Range Method

Patient Name : Dr.
N MAHEDHAR REDDY Collected : 04/Oct/2022 11:07AM

Age/Gender : 36 Y 0 M 0 D /M Received : 04/Oct/2022 11:23AM
UHID/MR No : DAWD.0000024622 Reported : 04/Oct/2022 12:37PM
Visit ID : DAWDOPV27202 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP LIGHT DIAGNOSTICS
IP/OP NO : Patient location : ELURU ROAD,VIJAYAWADA
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method
COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD-EDTA

HAEMOGLOBIN 15.1 g/dL 13-17 CYANIDE FREE
COLOUROMETER
PCV 43.80 % 40-50 PULSE HEIGHT AVERAGE
RBC COUNT 4.91 Million/cu.mm 4.5-5.5 Electrical Impedence
MCV 89.2 fL 83-101 Calculated
MCH 30.7 pg 27-32 Calculated
MCHC 34.5 g/dL 31.5-34.5 Calculated
R.D.W 12.9 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 6,500 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 58 % 40-80 Electrical Impedance
LYMPHOCYTES 32 % 20-40 Electrical Impedance
EOSINOPHILS 04 % 1-6 Electrical Impedance
MONOCYTES 06 % 2-10 Electrical Impedance
BASOPHILS 00 % <1-2 Electrical Impedance
CORRECTED TLC 6,500 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 3770 Cells/cu.mm 2000-7000 Electrical Impedance
LYMPHOCYTES 2080 Cells/cu.mm 1000-3000 Electrical Impedance
EOSINOPHILS 260 Cells/cu.mm 20-500 Electrical Impedance
MONOCYTES 390 Cells/cu.mm 200-1000 Electrical Impedance
PLATELET COUNT 203000 cells/cu.mm 150000-410000 IMPEDENCE/MICROSCOPY
Page 1 of 9
SIN No:HA04056083
Patient Name : Dr.N MAHEDHAR REDDY Collected : 04/Oct/2022 11:07AM
UHID/MR No : DAWD.0000024622 Reported : 04/Oct/2022 11:57AM
DEPARTMENT OF BIOCHEMISTRY
GLUCOSE, FASTING , NAF PLASMA 91 mg/dL 70-100 GOD - POD
Comment:
As per American Diabetes Guidelines
Fasting Glucose Values in mg/d L Interpretation
<100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
Page 2 of 9
SIN No:BI11253634
Age/Gender : 36 Y 0 M 0 D /M Received : 04/Oct/2022 12:36PM
HBA1C, GLYCATED HEMOGLOBIN , 4.6 % HPLC

WHOLE BLOOD-EDTA
ESTIMATED AVERAGE GLUCOSE (eAG) , 85 mg/dL Calculated
WHOLE BLOOD-EDTA
Comment:
Reference Range as per American Diabetes Association (ADA):
REFERENCE GROUP HBA1C IN %
NON DIABETIC ADULTS >18 YEARS <5.7
AT RISK (PREDIABETES) 5.7 – 6.4
DIAGNOSING DIABETES ≥ 6.5
DIABETICS
· EXCELLENT CONTROL 6–7
· FAIR TO GOOD CONTROL 7–8
· UNSATISFACTORY CONTROL 8 – 10
· POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable
glycemic control).
2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1
and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications
are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or
decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect
erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control
Page 3 of 9
SIN No:BI11253633
LIPID PROFILE , SERUM

TOTAL CHOLESTEROL 156 mg/dL <200 CHE/CHO/POD
TRIGLYCERIDES 69 mg/dL <150 Enzymatic
HDL CHOLESTEROL 45 mg/dL >40 CHE/CHO/POD
NON-HDL CHOLESTEROL 111 mg/dL <130 Calculated
LDL CHOLESTEROL 97.2 mg/dL <100 Calculated
VLDL CHOLESTEROL 13.8 mg/dL <30 Calculated
CHOL / HDL RATIO 3.47 0-4.97 Calculated
Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.
Desirable Borderline High High Very High

TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240
TRIGLYCERIDES <150 150 - 199 200 - 499 ≥ 500
Optimal < 100
LDL 130 - 159 160 - 189 ≥ 190
Near Optimal 100-129
HDL ≥ 60
Optimal <130;
NON-HDL CHOLESTEROL 160-189 190-219 >220
Above Optimal 130-159
Measurements in the same patient can show physiological and analytical variations.
NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
Page 4 of 9
SIN No:BI11253632
LIVER FUNCTION TEST (LFT) , SERUM

BILIRUBIN, TOTAL 1.30 mg/dL 0.20-1.20 DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT) 0.30 mg/dL 0.0-0.3 Calculated
BILIRUBIN (INDIRECT) 1.00 mg/dL 0.0-1.1 Dual Wavelength
ALANINE AMINOTRANSFERASE 36 U/L 21-72 UV with P-5-P
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 32.0 U/L 17-59 UV with P-5-P
(AST/SGOT)
ALKALINE PHOSPHATASE 51.00 U/L 38-126 p-nitrophenyl
phosphate
PROTEIN, TOTAL 6.60 g/dL 6.3-8.2 Biuret
ALBUMIN 4.00 g/dL 3.5 - 5 Bromocresol Green
GLOBULIN 2.60 g/dL 2.0-3.5 Calculated
A/G RATIO 1.54 0.9-2.0 Calculated
Page 5 of 9
SIN No:BI11253632
CALCIUM , SERUM 8.90 mg/dL 8.4 - 10.2 Arsenazo-III
Comments:-
Serum calcium measurements are done to monitor and diagnose disorders of skeletal system, parathyroid gland, kidney, muscular
disorders, and abnormal vitamin D and protein levels.
C-REACTIVE PROTEIN CRP 2.0 mg/L <10.0 IMMUNOENZYMATIC

(QUANTITATIVE) , SERUM
Comment:
C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. Measuring changes in the
concentration of CRP provides useful diagnostic information about the level of acuity and severity of a disease. Unlike ESR, CRP
levels are not influenced by hematologic conditions such as anemia, polycythemia etc.
Increased levels are consistent with an acute inflammatory process. After onset of an acute phase response, the serum CRP
concentration rises rapidly (within 6-12 hours and peaks at 24-48 hours) and extensively.Concentrations above 100 mg/L are
associated with severe stimuli such as major trauma and severe infection (sepsis).
Page 6 of 9
SIN No:BI11253632
ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) , SERUM

CREATININE 0.90 mg/dL 0.66-1.25 Creatinine
amidohydrolase
eGFR - ESTIMATED GLOMERULAR 109.49 mL/min/1.73m² >60 CKD-EPI FORMULA
FILTRATION RATE
Page 7 of 9
SIN No:BI11253632
DEPARTMENT OF IMMUNOLOGY
THYROID PROFILE (TOTAL T3, TOTAL T4, TSH) , SERUM

TRI-IODOTHYRONINE (T3, TOTAL) 1.03 ng/mL 0.7-2.04 CLIA
THYROXINE (T4, TOTAL) 8.60 µg/dL 6.09-12.23 CLIA
THYROID STIMULATING HORMONE 1.830 µIU/mL 0.34-5.60 CLIA
(TSH)
Comment:
Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night and the nadir occurring between
10 a.m. and 4 p.m.In primary hypothyroidism, thyroid-stimulating hormone (TSH) levels will be elevated. In primary
hyperthyroidism,TSH levels will be low. Elevated or low TSH in the context of normal free thyroxine is often referred to as
subclinical hypo- or hyperthyroid-ism, respectively. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients
on steroid therapy.
Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
Note:
Bio Ref Range for TSH in uIU/ml (As per
For pregnant females
American Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0
Page 8 of 9
SIN No:IM04406048
DEPARTMENT OF IMMUNOLOGY
VITAMIN B12 , SERUM 140 pg/mL 180-914 CLIA
Comment:
Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia,
loss of proprioception, poor coordination, and affective behavioral changes. A significant increase in RBC MCV may be an
important indicator of vitamin B12 deficiency.
Patients taking vitamin B12 supplementation may have misleading results. A normal serum concentration of B12 does not rule out
tissue deficiency of vitamin B12 . The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical
symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations
are normal.
TESTOSTERONE, TOTAL , SERUM 329.07 ng/dL 400-1080 CLIA
Comment:
Testosterone exhibits significant circadian variations in young men, and early morning samples are recommended.
Increased levels are seen in precocious puberty (males), androgen resistance, CAH, ovarian stromal hyperthecosis.
Decreased levels are seen in delayed puberty (males), gonadotropin deficiency, testicular feminization, estrogen therapy and certain
systemic diseases
*** End Of Report ***
Page 9 of 9
SIN No:IM04406048

Department of Haematology Test Name Result Unit Bio. Ref. Range Method

Uploaded by

Copyright:

Available Formats

Department of Haematology Test Name Result Unit Bio. Ref. Range Method

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Department of Haematology Test Name Result Unit Bio. Ref. Range Method

Uploaded by

Copyright:

Available Formats

Patient Name : Dr.

N MAHEDHAR REDDY Collected : 04/Oct/2022 11:07AM

COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD-EDTA

GLUCOSE, FASTING , NAF PLASMA 91 mg/dL 70-100 GOD - POD

HBA1C, GLYCATED HEMOGLOBIN , 4.6 % HPLC

LIPID PROFILE , SERUM

Desirable Borderline High High Very High

LIVER FUNCTION TEST (LFT) , SERUM

CALCIUM , SERUM 8.90 mg/dL 8.4 - 10.2 Arsenazo-III

C-REACTIVE PROTEIN CRP 2.0 mg/L <10.0 IMMUNOENZYMATIC

ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) , SERUM

THYROID PROFILE (TOTAL T3, TOTAL T4, TSH) , SERUM

VITAMIN B12 , SERUM 140 pg/mL 180-914 CLIA

TESTOSTERONE, TOTAL , SERUM 329.07 ng/dL 400-1080 CLIA

* End Of Report *

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.